Zinbryta Recall - Linked to Encephalitis, Meningoencephalitis, Brain Inflammation, Death

If you or a loved one used the drug Zinbryta to treat MS and developed a worsening, inflammatory brain disorder, such as encephalitis, meningoencephalitis or death resulting from these injuries, you may qualify for compensation from the manufacturer of the drug.

Zinbryta was pulled from the market after it was linked to 12 reports of patients who suffered “serious brain disorders,” including 3 patients in the United States who developed encephalitis. Other patients suffered life-threatening brain inflammation, meningoencephalitis, or death.

The FDA cited “concern about the drug’s evolving benefit/risk profile” while announcing Zinbryta’s withdrawal in the U.S. and around the world.

 

Dangerous Side Effects of Zinbryta

Zinbryta (daclizumab) is a multiple sclerosis injection drug that was introduced in 2016, for the treatment of adult patients with relapsing forms of multiple sclerosis.

  • Inflammatory encephalitis
  • Brain disorders
  • Encephalitis
  • Meningoencephalitis
  • Drug induced hepatitis,
  • Liver damage
  • Liver failure
  • Autoimmune hepatitis
  • Erythema multiforme
  • Stevens-Johnson syndrome (SJS)
  • Toxic Epidermal Necrolysis (TEN)
  • Skin reactions
  • Severe immune reactions
  • Inflammatory disorders
  • Immune toxicity
  • Hypersensitivity reactions
  • Blood dyscrasias
  • Thyroid inflammation (thyroiditis)
  • Glomerulonephritis
  • Death

 

Side Effects And Symptoms of Zinbryta

"The FDA cited “concern about the drug’s evolving benefit/risk profile” while announcing Zinbryta’s withdrawal in the U.S. and around the world."

Zinbryta (daclizumab) is made and marketed by Biogen and AbbVie. Zinbryta first received FDA approval pursuant to Biologic License Application (BLA: 761029) in May of 2016.  Zinbryta is a humanized monoclonal antibody that is self-administered as an injection for the treatment of Multiple Sclerosis.

In March of 2018 Biogen published a letter directed towards physicians and surgeons giving notice that Zinbryta would be withdrawn from the market and would no longer be available as of April 30, 2018.

The European Medicines Agency akso announced a recall of the drug after recording 12 reports of severe inflammatory brain disorders that developed after Zinbryta use, including at least three fatal cases.

Symptoms of brain inflammation can include:

  • Fever
  • Seizures
  • Changes in behavior
  • Confusion
  • Disorientation

Rate This Service

Did you or a loved one suffer an inflammatory brain disorder, such as Encephalitis, Meningoencephalitis, Sudden Brain Inflammation or Wrongful Death after using the recalled drug Zinbryta to treat MS?

Find out if you may qualify for compensation.

Find Out More
Copyright © 2016-2017 Consumer Safety Watch. All Rights Reserved. Privacy / Terms / Disclaimer

Consumer Safety Watch offers safety advocate services and attorney referral services for patients throughout the United States including the states of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin and Wyoming.

Consumer Safety Watch offers consumer safety advocate services or can help you find an attorney throughout the United States including the following cities: Albuquerque, NM; Arlington, TX; Atlanta, GA; Austin, TX; Baltimore, MD; Boston, MA; Charlotte, NC; Chicago, IL; Cleveland, OH; Colorado Springs, CO; Columbus, OH; Dallas, TX; Denver, CO; Detroit, MI; Fresno, CA; Fort Worth, TX; Indianapolis, IN; Honolulu, HI; Houston, TX; Jacksonville, FL; Kansas City, KS; Kansas City, MO; Las Vegas, NV; Long Beach, CA; Los Angeles, CA; Louisville, KY; Memphis, TN; Mesa, AZ; Miami, FL; Miami, OH; Milwaukee, WI; Minneapolis, MN; Nashville, TN; New York City, NY; Oakland, CA; Oklahoma City, OK; Omaha, NE; Philadelphia, PA; Phoenix, AZ; Pittsburgh, PA; Portland, OR; Sacramento, CA; San Antonio, Tx; San Diego, CA; San Francisco, CA; San Jose, CA; Seattle, WA; St. Louis, MO; Tampa, FL; Tucson, AZ; Tulsa, Virginia Beach, VA; Washington, DC; Wichita, KS.